Ravi Salgia to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications Ravi Salgia has written about TOR Serine-Threonine Kinases.
Connection Strength
0.685
-
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
Score: 0.455
-
Overexpression of the ยต-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012 Apr; 116(4):857-67.
Score: 0.096
-
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010 Jun 11; 285(24):18575-85.
Score: 0.083
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.037
-
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23.
Score: 0.014